48663 Results for: "3,3-Dimethylglutaric+acid&pageNo=8"

Supplier: Enzo Life Sciences

A guggul tree steroid well known for its lipid lowering properties. Acts as a selective antagonist at farnesoid X receptors (FXRs). Inhibits FXR transactivation (IC50=10µM).

Supplier: Enzo Life Sciences

Highly potent and selective serotonin uptake inhibitor

Supplier: Enzo Life Sciences

Inhibitor of dopamine and norepinephrine transporters

Supplier: Enzo Life Sciences

K+ channel blocker

Supplier: Enzo Life Sciences

Lysophosphatidic acid (LPA) receptor ligand. A specific agonist at LPA2 (EC₅₀=700 nM) and antagonist at LPA.

Supplier: Enzo Life Sciences

Calcineurin substrate

Supplier: Enzo Life Sciences

Potent and selective leukocyte elastase inhibitor (IC50=44nM). Displays various anti-inflammatory activities including attenuation of LTB4-induced neutrophil migration and serum cytokine levels. Reduces acute inflammatory lung injury in vivo.

Supplier: Enzo Life Sciences

Specific non-chelating small-molecule inhibitor of MMP-12 (IC50 = 14 nM). At higher concentrations it inhibits other MMPs, but spares MMP-1, making it a valuable tool for investigation of MMP activity and function.

Supplier: Enzo Life Sciences

PDE inhibitor

Supplier: Enzo Life Sciences

Calpain and cathepsin inhibitor

Supplier: Enzo Life Sciences

Selective, dual inhibitor of PDE III and PDE IV (IC50s=2.5 and 1.1 µM respectively). Anti-allergic activity, combined inhibition of PDE III and IV have an additive synergistic effect on inhibition of guinea pig bronchospasm.

Supplier: Enzo Life Sciences

R-enantiomer of rolipram which is more active at inhibition of PDE IV, Ki=06 µM. 10-fold more active than S-rolipram at inhibition of PDE IV. Inhibits antigen-induced contraction of guinea-pig colonic smooth muscle, EC50=0.1 µM.

Supplier: Enzo Life Sciences

Adrenergic receptor ligand.

Supplier: Enzo Life Sciences

PARP inhibitor

Supplier: Enzo Life Sciences

TRPA1 activator.

Supplier: Enzo Life Sciences

A potent chloride channel blocker (IC50=0.1-100 µM depending on channel subtype and assay method). Inhibits cyclooxygenase (COX; IC50=8 µM). Evidence of mitochondrial uncoupling in mouse peritoneal macrophages, due to protonophore activity.

Supplier: Enzo Life Sciences

TRPV1 antagonist

Supplier: Enzo Life Sciences

Cl⁻ channel blocker.

Supplier: Enzo Life Sciences

Cell-permeable PKC inhibitor. Selective for PKC (IC50=10nM) over CaM kinase II (IC50=17µM) and PKA (IC50=0.9µM). Induces apoptosis in various cell lines.

Supplier: Enzo Life Sciences

HNMPA is a membrane impermeable inhibitor of insulin receptor tyrosine kinase (IC50 = 100µM); in rat adipocytes (IC50 = 10µM). Inhibits serine and tyrosine autophosphorylation by the human insulin receptor.

Supplier: Enzo Life Sciences

Inhibits the translocation of Akt.

Supplier: Enzo Life Sciences

URB-597 is a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), which is involved in the hydrolysis of endogenous cannabinoids such as anandamide. Inhibition of FAAH may serve to enhance the analgesic effects of endogenous cannabinoids. URB-597 has been shown to inhibit FAAH in rat cortical neuron membranes and in intact neurons with IC50 values of 4.6nM and 0.5nM, respectively. The compound has also been shown to have anxiolytic effects in rats (ID50=0.15mg/kg). Because URB-597 acts on FAAH and does not interfere with the binding of anandamide to the CB1 and CB2 receptors, it is a novel tool for drug development.

Supplier: Enzo Life Sciences

Tyrosine kinase inhibitor. It has been shown to block TNFα induced cytotoxicity and to block glucocorticoid-induced COX-2 activity in human amnion cells (IC50=21μM). It is also reported to inhibit guanylyl cyclase.

Supplier: Enzo Life Sciences

Retinoic acid receptor ligand.

Supplier: Enzo Life Sciences

Retinoic acid receptor ligand

Supplier: Enzo Life Sciences

Endogenous [1] ligand for the CB1 receptor (CB1: Ki=52nm; CB2: Ki=1930nm [2]) and TRPV1 (Ki=5.78µM [3,4]). Inhibits NF-κB activation through direct binding to IKKβ [5] and induces apoptosis independently of cannabinoid or vanilloid receptors [6]. Activates the MAP kinase (MAPK/ERK) signalling pathway [7].

Supplier: Enzo Life Sciences

Endogenous cannabinoid. Weak ligand of CB1 (Ki=23.8µM) and CB2 (Ki=13.9µM) receptor. Inhibits fatty acid amide hydrolase (FAAH) (IC50=5.1µM). Immunosuppressant, anti-inflammatory, anti-nociceptive and anti-convulsant in vivo. The exact mode of action has not yet been revealed. It has been suggested that PEA: i) binds to a yet to be discovered cannabinoid receptor similar to CB2; ii) administered in vivo elicits the synthesis of endogenous agonists of CB2; iii) acts as an "entourage" compound by enhancing the activity and/or by influencing the turnover of endogenous agonists of CB2, possibly but not uniquely, by inhibiting their degradation.

Supplier: Enzo Life Sciences

Putative endogenous member of a growing family of lipo-amino acids (N-acyl amino acids).

Supplier: Enzo Life Sciences

Cannabinoid receptor ligand.

Supplier: Enzo Life Sciences

Arachidonic acid analog.